New Zealand · Funded startup

Who invested in Toku Eyes

One round we have observed, with the 2 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Healthcare

Funding summaryUpdated 26 Oct 2026

$2.5Mraised across 1 round since 2024, from 1 source

Latest round
Grant, $2.5MSept 2024
Investors
2
See who backed them

The rounds

  1. Sept 2024
    Grant$2.5M

    Source recorded

Founders and team

From Toku Eyes's own website: 4 on the team.

  • Ben McCallumChief Operations Officer
  • Francesca LoganChief Commercial Officer
  • Kate BlackbournChief Product Officer
  • Michael V. McConnellChief Health Officer

AdvisersTheodore Leng

Everyone who backed them

Callaghan InnovationInvestment firm1round
Icehouse VenturesVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Toku Eyes as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

Ice AngelsAngel networkPer its own site

Quick answers about Toku Eyes

Who invested in Toku Eyes?

Toku Eyes's investors include Callaghan Innovation and Icehouse Ventures.

How much has Toku Eyes raised?

Toku Eyes has raised $2.5M across 1 round since 2024.

When did Toku Eyes last raise?

Toku Eyes's most recent round was a Grant of $2.5M in Sept 2024.

What was Toku Eyes's biggest round?

Its most recent round, $2.5M in Sept 2024, is also its largest on record.

Who backed Toku Eyes first?

Toku Eyes's first round on record, in Sept 2024, was backed by Callaghan Innovation and Icehouse Ventures.

What stage is Toku Eyes at?

Toku Eyes's latest named round is a Grant, in Sept 2024.

Where is Toku Eyes based?

Toku Eyes is based in New Zealand.

Companies like Toku Eyes

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.